Document is current
Any future updates will be listed below
-
Authors
Bellomo, Giovanni
Stoops, Erik
Vanbrabant, Jeroen
Demeyer, Leentje
Francois, Cindy
Vanhooren, Melanie
Ma, Yihua
Farris, Carly M.
Concha-Marambio, Luis
Paolini Paoletti, Federico
Gaetani, Lorenzo
Parnetti, Lucilla
Chiasserini, Davide
-
Funding
Funding for this research was provided by:
Parkinson's Disease Foundation (PF-PRF-934916)
NextGenerationEU (PNRR-MAD-2022-12376035, PNRR-MAD-2022-12376035)
- License Information
-
More Information
Article History
Received: 29 March 2025
Accepted: 19 July 2025
First Online: 7 August 2025
Competing interests
: The authors declare the following competing financial interests: G. Bellomo and L. Gaetani completed paid consultancies for Fujirebio Europe. E. Stoops, J. Vanbrabant, L. Demeyer, C. Francois, M. Vanhooren are employees of ADx NeuroSciences. L. Concha-Marambio, C. Farris, and Y. Ma are inventors of several patents related to SAA technology (PMCA) and are associated with Amprion Inc., a biotech company focused on the commercial utilization of SAA for diagnosis. L. Parnetti served as an Advisory Board Member for Fujirebio, IBL, Roche, and Merck. The other authors declare no financial and non-financial competing interests.
